Join Sidley’s Life Sciences team for an afternoon of thought-provoking and engaging discussions touching on the latest trends and hot topics including the new administration, new technologies, the investment landscape, and more.
This year's fifth annual event will be held in the stunning Institute of Contemporary Art/Boston lobby, followed by a reception on the picturesque harbor front plaza.
Please see below for details on our newly announced panels and panelists.
WHO SHOULD ATTEND
Executives, Investors, General Counsel, and Company Counsel
AGENDA
Registration: 1:30 p.m. ET
Program: 2:00 p.m. ET
Reception: 5:00 p.m. – 6:30 p.m. ET
FEATURED PANEL TOPICS
The New Administration, Trade Wars, and GC Strategies For Managing A Changing Environment
As the New Administration brings personnel and policy changes to HHS and FDA, and trade wars add new considerations for product development and manufacturing, we reflect on key developments and strategies GCs use to successfully manage the opportunities and risks in a changing environment.
- Lana Gladstein, General Counsel, Seaport Therapeutics
- Jose Truzman, General Counsel - U.S., Intercept Pharmaceuticals, Inc.
- Aaron Applebaum, Counsel, Global Arbitration, Trade and Advocacy
- Jackson Garvey, Partner, Restructuring & Liability Management
- Becky Wood, Partner, Global Co-leader, Food, Drug and Medical Device and Former Chief Counsel, FDA
New Product Development Pathways for Success
This panel will discuss key areas of focus during product development to set companies up for success, including the use of artificial intelligence (AI), pre-approval compliance considerations, and pricing strategies.
- Meena Datta, Partner, Global Co-leader, Healthcare
- Deeona Gaskin, Partner, Food, Drug and Medical Device and Former Associate Chief Counsel for Enforcement, FDA
Navigating Life Sciences Transactions in a Dynamic Economic Landscape
This panel will discuss the evolving landscape of life sciences transactions, including emerging trends in the current investment climate.
- Shaan Gandhi, Head of Strategic Partnerships, Pfizer Ignite
- Paresh Kumar, Vice President, Biotech Private Equity, Ally Bridge Group
- Jason Tse, Vice President Corporate Development, McKesson
- Chris York, Vice President, General Counsel & Chief of Staff, Orchard Therapeutics
- Mat Eapen, Partner, Investment Funds
KEYNOTE ADDRESS
"Get Your Mindset Right": Thriving in Change
A Conversation with Kirk Taylor, MD on Navigating Changing Times
Kirk Taylor, MD
President & CEO
Massachusetts Life Sciences Center
Kirk Taylor, MD is a global pharmaceutical executive with expertise in Phase II – IV drug development, including CNS, oncology and rare disease. As Chief Medical Officer, Chief Strategy Officer and SVP Medical Affairs, he has restructured organizations, created strategic operating plans, and shaped corporate culture. His entrepreneurial acumen assisted in leading biotech start-up companies to successful IPOs and multiple funding rounds. He is people-first focused, leading teams with respect and innovation. In recognition of his positive impact, he was awarded the 2023 PharmaVoice 100 Executives Award.
Dr. Taylor received his Bachelor of Arts from Harvard College and studied piano at the Longy School of Music in Cambridge. He completed his Doctor of Medicine from the State University of New York, Downstate, his neurology residency at Einstein College of Medicine, and a post-doc at UCSF.
